|Bid||16.10 x 1700|
|Ask||16.15 x 400|
|Day's Range||15.77 - 16.45|
|52 Week Range||7.02 - 18.50|
|PE Ratio (TTM)||-7.78|
|Earnings Date||Aug 7, 2017 - Aug 11, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||24.38|
Investors in Epizyme (EPZM) need to pay close attention to the stock based on moves in the options market lately.
Path Toward Submission for Accelerated Approval. Tazemetostat Demonstrates Clinically Meaningful Activity in Epithelioid Sarcoma; Interim Phase 2 Epithelioid Sarcoma and Synovial Sarcoma Data to be Presented ...
On May 16, we issued an updated research report on La Jolla, CA based Orexigen Therapeutics, Inc. (OREX). Orexigen is a biopharmaceutical company focused on the development of obesity treatments.